Published on FierceVaccines (http://www.fiercevaccines.com)

After lengthy delay, GSK to release vax data; Anthrax vax makers see shares drop;

By john
Created Apr 23 2009 - 8:44am

Vaccine Research

After waiting for more than a year, GlaxoSmithKline says it is now ready to release data on a head-to-head clinical study comparing its cervical cancer vaccine against Merck's. And one expert says that the lengthy wait has raised both his eyebrows. Report [1]

The New Scientist magazine reports on the progress of a team of Harvard researchers studying a new universal flu vaccine. Story [2]

An experimental ebola vaccine has demonstrated its safety in STAT-1 knockout-mice and evaluated its protective efficacy in mice and guinea pigs. Release [3]

A Phase IIb proof-of-concept clinical trial of a promising new TB vaccine developed at the University of Oxford--called MVA85A/AERAS-485--has been launched. Release [4]

Vical announced the publication of data from preclinical studies identifying potential targets for development of a herpes simplex virus type 2 vaccine. Release [5]

The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. Release [6]

Vaccine Market

Shares of several vaccine makers were dragged down earlier in the week after the government asked the bidders on a new anthrax vaccine contract to submit a comprehensive regulatory plan in 15 days. Report [7]

Wyeth is donating three million doses of Prevnar to two African counties in the first national immunization programs aimed at pneumococcal disease in a developing nation. Story [8]

A meningitis epidemic is sweeping West Africa at a time when global supplies of meningitis vaccine are low. Story [9]

A sixth case of measles has been reported in the Washington area. Report [10]

Source URL: